6 Investor presentation First nine months of 2022 Diabetes value market leadership 31.6% Novo Nordisk global diabetes value market shares 60% 50% 46.8% 44.3% 40% 30% 28.4% Diabetes 49.9% GLP-1 Insulin 52.1% 44.6% 44.0% 29.2% 29.9% 55.7% 44.2% 31.6% 200%% 2019 2020 2021 CER: Constant exchange rates; IO: International Operations; NAO: North America Operations Source: IQVIA MAT, Aug 2022 (Spot rate) Note: Sales growth rates are at CER 2022
Download PDF file